These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9673439)

  • 1. Pituitary-adrenal responses to combined oral D-fenfluramine and intravenous naloxone in humans.
    Grice JE; Torpy DJ; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    Clin Exp Pharmacol Physiol; 1998; 25(7-8):621-3. PubMed ID: 9673439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fenfluramine on episodic ACTH and cortisol secretion.
    Schürmeyer TH; Brademann G; von zur Mühlen A
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):39-45. PubMed ID: 8796137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diurnal effects of fluoxetine and naloxone on the human hypothalamic-pituitary-adrenal axis.
    Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    Clin Exp Pharmacol Physiol; 1997 Jun; 24(6):421-3. PubMed ID: 9171947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stress hormone dysregulation at rest and after serotonergic stimulation among alcohol-dependent men with extended abstinence and controls.
    Anthenelli RM; Maxwell RA; Geracioti TD; Hauger R
    Alcohol Clin Exp Res; 2001 May; 25(5):692-703. PubMed ID: 11411461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine.
    Boushaki FZ; Rasio E; Serri O
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):461-6. PubMed ID: 9196609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of flumazenil on basal and naloxone-stimulated ACTH and cortisol release in humans.
    Torpy DJ; Jackson RV; Grice JE; Hockings GI; Crosbie GV; Walters MM
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):157-61. PubMed ID: 8039271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium valproate on naloxone-stimulated ACTH and cortisol release in humans.
    Torpy DJ; Grice JE; Hockings GI; Crosbie GV; Walters MM; Jackson RV
    Clin Exp Pharmacol Physiol; 1995; 22(6-7):441-3. PubMed ID: 8582096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man.
    Inder WJ; Ellis MJ; Evans MJ; Donald RA
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):425-31. PubMed ID: 7586616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides.
    Inder WJ; Joyce PR; Ellis MJ; Evans MJ; Livesey JH; Donald RA
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):283-90. PubMed ID: 7586596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 2: response to ovine corticotropin-releasing factor and naloxone.
    Adinoff B; Krebaum SR; Chandler PA; Ye W; Brown MB; Williams MJ
    Alcohol Clin Exp Res; 2005 Apr; 29(4):528-37. PubMed ID: 15834217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between the stimulated hypothalamic-pituitary-adrenal axis and leptin in humans.
    Nye EJ; Bornstein SR; Grice JE; Tauchnitz R; Hockings GI; Strakosch CR; Jackson RV; Torpy DJ
    J Neuroendocrinol; 2000 Feb; 12(2):141-5. PubMed ID: 10718909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation.
    Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson AJ; Jackson RV
    J Clin Endocrinol Metab; 1993 Aug; 77(2):404-8. PubMed ID: 8393884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.
    Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME
    Addict Biol; 2013 Jan; 18(1):181-92. PubMed ID: 22264217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothalamic amenorrhea: evidence for a central derangement of hypothalamic-pituitary-adrenal cortex axis activity.
    Nappi RE; Petraglia F; Genazzani AD; D'Ambrogio G; Zara C; Genazzani AR
    Fertil Steril; 1993 Mar; 59(3):571-6. PubMed ID: 8384575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of a disturbance of the hypothalamic-pituitary-adrenal axis in polycystic ovary syndrome: effect of naloxone.
    Lanzone A; Guido M; Ciampelli M; Fulghesu AM; Pavone V; Proto C; Caruso A; Mancuso S
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):73-7. PubMed ID: 8796141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of HPA axis hyperactivity on hormonal responses to d-fenfluramine in major depressed patients: implications for pathogenesis of suicidal behaviour.
    Duval F; Mokrani MC; Correa H; Bailey P; Valdebenito M; Monreal J; Crocq MA; Macher JP
    Psychoneuroendocrinology; 2001 Jul; 26(5):521-37. PubMed ID: 11337135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome.
    Scott LV; Burnett F; Medbak S; Dinan TG
    Psychol Med; 1998 Mar; 28(2):285-93. PubMed ID: 9572086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diurnal variations in endocrine and psychological responses to 0.2 mg/kg naloxone administration in patients with major depressive disorder and matched controls.
    Martín del Campo AF; Dowson JH; Herbert J; Paykel ES
    J Affect Disord; 2000; 57(1-3):37-47. PubMed ID: 10708814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients.
    Clark DJ; Lipworth BJ
    Chest; 1997 Nov; 112(5):1248-52. PubMed ID: 9367464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.